Skip to main content
Mazyar Shadman, MD, Oncology, Seattle, WA, Fred Hutchinson Cancer Center

MazyarShadmanMDMPH

Oncology Seattle, WA

Hematologic Oncology

Associate Professor of Medicine - Medical Oncology - University of Washington Associate Professor, Clinical Research Division, Fred Hutchinson Cancer Research Center

Dr. Shadman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Shadman's full profile

Already have an account?

Education & Training

  • University of Washington
    University of WashingtonFellowship, Hematology and Medical Oncology, 2011 - 2014
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Internal Medicine, 2008 - 2011
  • University of Washington
    University of WashingtonMPH, Cancer Epidemiology , 2006 - 2008
  • Tehran University of Medical Sciences School of Medicine
    Tehran University of Medical Sciences School of MedicineClass of 2004

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2011 - 2025
  • OH State Medical License
    OH State Medical License 2008 - 2011

Awards, Honors, & Recognition

  • Trainee Research Award American Society of Hematology (ASH)

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Translating Anti-CD19 CAR T-cell Therapy into Clinical Practice for relapsed/refractory Diffuse Large B-cell Lymphoma  
    Mazyar Shadman, Ajay K Gopal, Victor A Chow, Blood

Abstracts/Posters

  • High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials
    Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
    Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Resu...
    Mazyar Shadman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Join now to see all

Press Mentions

  • High CLL Therapy Cessation Rates in Real World Practice
    High CLL Therapy Cessation Rates in Real World PracticeApril 17th, 2023
  • Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy
    Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T TherapyJune 13th, 2022
  • Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
    Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate HighlightsNovember 12th, 2021
  • Join now to see all

Professional Memberships

Hospital Affiliations